Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COR 
Cencora Inc. (COR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: COR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $333.29
1 Year Target Price $333.29
| 10 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 31.57% | Avg. Invested days 59 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 56.50B USD | Price to earnings Ratio 29.95 | 1Y Target Price 333.29 |
Price to earnings Ratio 29.95 | 1Y Target Price 333.29 | ||
Volume (30-day avg) 17 | Beta 0.62 | 52 Weeks Range 216.84 - 308.18 | Updated Date 09/16/2025 |
52 Weeks Range 216.84 - 308.18 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 0.71% | Basic EPS (TTM) 9.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.6% | Operating Margin (TTM) 1.22% |
Management Effectiveness
Return on Assets (TTM) 3.1% | Return on Equity (TTM) 116.71% |
Valuation
Trailing PE 29.95 | Forward PE 17.3 | Enterprise Value 64660570560 | Price to Sales(TTM) 0.18 |
Enterprise Value 64660570560 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA 16.09 | Shares Outstanding 193878000 | Shares Floating 185610928 |
Shares Outstanding 193878000 | Shares Floating 185610928 | ||
Percent Insiders 4.2 | Percent Institutions 94.03 |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora Inc., formerly AmerisourceBergen, was founded in 1985 (through a merger) but traces its roots back further. It has grown through acquisitions and organic growth to become a leading global pharmaceutical distributor.
Core Business Areas
- U.S. Healthcare Solutions: Distributes branded and generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies in the U.S.
- International Healthcare Solutions: Provides pharmaceutical distribution and other services outside of the U.S.
Leadership and Structure
Steven H. Collis is the Chairman, President & CEO. The company has a typical corporate structure with executive leadership over various business units and functions.
Top Products and Market Share
Key Offerings
- Pharmaceutical Distribution: Distributes a wide range of pharmaceuticals to pharmacies, hospitals, and healthcare providers. Market share information is embedded in the Market Dynamics section. McKesson, Cardinal Health are main competitors.
- Specialty Pharmaceutical Services: Provides services related to specialty pharmaceuticals, including distribution, reimbursement support, and patient services. Competitors include McKesson, Cardinal Health and specialty pharmacies.
- Global Sourcing: Sourcing of Active Pharmaceutical Ingredients (API's) and generics globally to obtain lower cost products. Competitors include McKesson, Cardinal Health.
Market Dynamics
Industry Overview
The pharmaceutical distribution industry is consolidated, with a few major players dominating the market. It is heavily regulated and subject to pricing pressures.
Positioning
Cencora Inc. is one of the top three pharmaceutical distributors in the US, along with McKesson and Cardinal Health. Its size and scale provide competitive advantages.
Total Addressable Market (TAM)
The global pharmaceutical distribution market is estimated at hundreds of billions of dollars. Cencora Inc. holds a significant position, estimated around 20-25% in the markets it operates in.
Upturn SWOT Analysis
Strengths
- Large scale and market share
- Extensive distribution network
- Strong relationships with manufacturers and pharmacies
- Diversified service offerings
- Global Sourcing
Weaknesses
- Reliance on a few large customers
- Exposure to pricing pressures
- Regulatory risks
- Debt Levels
Opportunities
- Growth in specialty pharmaceuticals
- Expansion into emerging markets
- Increased demand for healthcare services
- Acquisitions of smaller players
- Expanded 3PL offerings
Threats
- Increased competition
- Changes in healthcare regulations
- Drug pricing reforms
- Economic downturn
- Cybersecurity risks
- Disruptions to the supply chain
Competitors and Market Share
Key Competitors
- McKesson Corporation (MCK)
- Cardinal Health, Inc. (CAH)
Competitive Landscape
Cencora Inc. competes with McKesson and Cardinal Health on price, service, and product offerings. Cencora Inc. is slightly smaller than McKesson and similar in size to Cardinal Health.
Major Acquisitions
PharMEDium Healthcare
- Year: 2015
- Acquisition Price (USD millions): 2575
- Strategic Rationale: Expanded Cencora Inc.'s presence in the sterile compounding market.
Growth Trajectory and Initiatives
Historical Growth: Cencora Inc. has grown organically and through acquisitions.
Future Projections: Analyst estimates project continued growth in revenue and earnings, driven by growth in the pharmaceutical market and strategic initiatives.
Recent Initiatives: Recent initiatives may include acquisitions, expansion into new markets, and investments in technology.
Summary
Cencora Inc. is a large pharmaceutical distributor with a strong market position. The company benefits from its scale and relationships, but faces pricing pressures and regulatory risks. Future growth depends on capitalizing on opportunities in specialty pharmaceuticals and emerging markets, while mitigating competitive threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
- Company Website
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 51000 | Website https://www.cencora.com |
Full time employees 51000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.